NASDAQ: LBRXLb Pharmaceuticals Inc Stock Ownership - Who owns Lb Pharmaceuticals?
Insider buying vs selling
Have Lb Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund Ltd | 10% Owner | 2025-09-12 | 2,000,000 | $15.00 | $30.00MBuy |
| Deep Track Biotechnology Master Fund Ltd | 10% Owner | 2025-09-12 | 666,666 | $15.00 | $10.00MBuy |
| Ran Nussbaum | Director | 2025-09-12 | 1,000,000 | $15.00 | $15.00MBuy |
| Pontifax Management 4 GP 2015 Ltd | 10% Owner | 2025-09-12 | 1,000,000 | $15.00 | $15.00MBuy |
| Vida Ventures GP III LLC | 10% Owner | 2025-09-12 | 332,566 | $15.00 | $4.99MBuy |
| Vida Ventures GP III LLC | 10% Owner | 2025-09-12 | 767 | $15.00 | $11.51kBuy |
LBRX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when LBRX insiders and whales buy or sell their stock.
LBRX Shareholders
What type of owners hold Lb Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Deep Track Biotechnology Master Fund Ltd | 11.69% | 3,352,804 | $134.38M | Insider |
| Deep Track Capital LP | 11.69% | 3,352,804 | $134.38M | Institution |
| Blackrock Inc | 8.62% | 2,470,845 | $99.03M | Institution |
| Ra Capital Management LP | 7.70% | 2,208,604 | $88.52M | Institution |
| Tcg Crossover Management LLC | 6.41% | 1,839,489 | $73.73M | Institution |
| Commodore Capital LP | 5.23% | 1,500,000 | $60.12M | Institution |
| Caligan Partners LP | 5.01% | 1,438,070 | $57.64M | Institution |
| Jpmorgan Chase Co | 4.98% | 1,427,568 | $57.22M | Institution |
| Pontifax Management 4 GP 2015 Ltd | 4.92% | 1,411,681 | $56.58M | Insider |
| Ran Nussbaum | 4.92% | 1,411,681 | $56.58M | Insider |
LBRX vs Biotech Stocks
Lb Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.